Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ningbo David Medical Device Co., Ltd. (300314.SZ)
Ningbo, CN
Ningbo David Medical Device Co., Ltd. is a global enterprise dedicated to the innovation, production, and worldwide distribution of medical equipment. The company's primary focus lies in providing essential neonatal care devices, such as infant incubators, transport incubators, infant radiant warmers, and phototherapy units for neonatal bilirubin. They also supply infant resuscitators. Beyond these core offerings, Ningbo David Medical Device Co., Ltd. manufactures a diverse range of other medical apparatus. These include infusion pumps, transcutaneous jaundice detectors, infant T-piece resuscitators, air/oxygen blenders, low-pressure aspirators, infant oxygen hoods, far infrared heaters, and infant head-fixing units. All products are marketed under the "David" brand. Established in 1992, the company maintains its headquarters in Ningbo, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -6.34% | -11.61% | -30.42% | -23.94% | -18.92% | -18.14% | -52.65% | -37.65% | -54.46% | +22.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+10.2% Q1'26: -6.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+50.0% ★ Q1'26: -56.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+6.3% Q1'26: -44.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+12.1% ★ Q1'26: +10.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+10.5% ★ Q1'26: +6.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.6% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.06× ★ Q1'26: 0.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
300.30M
est: 366.67M (-18.1%)
|
527.03M
est: 780.11M (-32.4%)
|
580.52M
est: 981.38M (-40.8%)
|
| EBITDA |
61.06M
est: 83.53M (-26.9%)
|
87.03M
est: 180.27M (-51.7%)
|
99.64M
est: 226.78M (-56.1%)
|
| EBIT |
40.30M
est: 65.65M (-38.6%)
|
64.24M
est: 143.51M (-55.2%)
|
70.08M
est: 180.54M (-61.2%)
|
| Net Income |
28.81M
|
57.26M
est: 201.60M (-71.6%)
|
87.05M
est: 250.56M (-65.3%)
|
| SGA |
80.09M
est: 84.35M (-5.1%)
|
172.44M
est: 221.87M (-22.3%)
|
92.06M
est: 279.12M (-67.0%)
|
| EPS |
0.10
|
0.20
est: 0.70 (-71.4%)
|
0.30
est: 0.87 (-65.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 3.8K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 8.6K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 425.9K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 684.29 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.1K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.1K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 488.32 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 56.39 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 18.54 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 8.83 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ding Yu Lin | Deputy General Manager | — | male |
| Wenqian Zhou | Deputy General Manager | — | male |
| Yanjun Liu | Accounting Supervisor | — | — |
| Yongwei Yu | Deputy GM & Non-Independent Director | — | male |
| Zaihong Chen | GM & Chairman | — | male |
| Zedong Li | Chief Financial Officer & Director | — | male |
| Zhi'ang Chen | Secretary & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300314.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
